Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agentsXue Gao, David R. Liu, David B. Thompson et al.|Nature|2017Cited by 547
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivoYong Tao, Zheng‐Yi Chen, Verónica Lamas et al.|Nature Communications|2023Cited by 49
In Vivo Assessment of Potential Therapeutic Approaches for USH2A-Associated DiseasesNachiket Pendse, Qin Liu, Verónica Lamas et al.|Advances in experimental medicine and biology|2019Cited by 32
Exon 13-skipped USH2A protein retains functional integrity in mice, suggesting an exo-skipping therapeutic approach to treat USH2A-associated diseaseNachiket Pendse, Qin Liu, Morgan L. Maeder et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 9